All In MedTech

Device Trial Radar · NCT04496518

Personalized Therapy Study - Intrinsic Antitachycardia Pacing Post-Approval Study (iATP PAS)

Last checked: Nov 20, 2026Latest source record: Oct 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

2,200

Planned (sponsor's estimate)

Start

Aug 1, 2020

Primary completion

Nov 6, 2024

Study completion Jan 31, 2028

Sponsor

Lead sponsor
MedtronicPublic (MDT)
Sponsor type
Industry
First posted
Aug 3, 2020

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Medtronic is sponsoring the Intrinsic Antitachycardia Pacing Post-Approval Study (iATP PAS) to further confirm safety and effectiveness of ventricular iATP therapy in routine clinical practice, following commercial release of iATP-capable devices. The iATP PAS is conducted within Medtronic's Product Surveillance Registry platform (NCT01524276).

Conditions

  • Ventricular Tachycardia

Interventions

  • Intrinsic Antitachycardia Pacing (iATP) TherapyDevice

    iATP is a fully automated ATP therapy for monomorphic ventricular tachycardia (MVT).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To demonstrate the success rate of iATP in the fast VT (FVT) zone is greater than 60%Time frame: Approximately 5 years

Locations

92 sites in 9 countries. Site status is shown where the registry gives one.

  • Southwest EP

    Chandler, Arizona

  • Saint Vincent Heart Clinic Arkansas

    Little Rock, Arkansas

  • Chula Vista Cardiac Center

    Chula Vista, California

89 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.